Cell therapy has shown beneficial effects on ventricular function and tissue regeneration in patients with acute and chronic myocardial infarction, although with diverse grades of variability in the results, possibly by proportion, subtype and cell cycle status. Objective: Identify and phenotypically characterize, via CXCR4 and SDF-1 expression, the bone marrow cell subpopulations that are mobilized into the bloodstream in patients with Acute Myocardial Infarction (AMI) and Acute Ischemia (AI) such as acute angina and Chronic Ischemia (CI) such as chronic stable angina, and also determine the cell cycle status of these cells. Method: Patients with AMI and AI were recruited in the ICCU, and patients with CI in the departments of cardiology and cardiovascular surgery. The quantification of cellular subpopulations was made by cytofluorometry with a FACS caliburcyto fluorometry (Becton Dickinson) with specific FITC-labeled anti human monoclonal antibodies against CD34, CD133, CD117, CD48, CXCR4, SDF-1 and Ki67 (Becton Dickinson). Serum concentration of IL-6 and IL-8 were determined by a sequential solid phase chemiluminescent assay performed in a SIEMENS IMMULITE 1000 Analyzer. Statistical analysis was made with the SPSS version 20.0 for Windows. A <i>p</i> value < 0.05 was considered as statistical significant. Results: We analyzed 174 patients. 67 had Acute Myocardial Infarction, 55 Acute Ischemia and 52 Chronic Ischemia. Total cellularity of bone marrow and SDF-1+ cells was significantly higher in patients with AMI (14.6 ± 1.5 × 10<sup>3</sup>/ml) than that in AI (9.2 ± 1.3 × 10<sup>3</sup>/ml) and CI (6.6 ± 1.1 × 103/ml) patients (<i>p</i> < 0.001). There were no significant differences in the amount of CD34+, CD117+, CD133+ and CD48+ cells between AMI (49.9 ± 3.9, 45 ± 4.7, 43.2 ± 3.7, 35.4 ± 6.7 respectively) and AI (36.7 ± 2.5, 36 ± 3.2, 33.7 ± 5.1, 32 ± 5 respectively) patients (<i>p</i> = 0.22 to 0.39), but interestingly in AMI and AI patients, cells were CXCR4+ in almost half of these mobilized cells, although the proportion was significantly higher in AMI patients (46.8% ± 7.1% to 55.7% ± 6.3% vs 23% ± 1.6% to 28.4% ± 2.1%, <i>p</i> = 0.03 to 0.05). A similar behavior was observed with the Ki67 antibody (29.9% ± 2.1% to 36.1% ± 6.3% vs 10% ± 1.2% to 24% ± 1.1%, <i>p</i> = 0.001 to 0.05). Bivariate analysis of the results showed a significant correlation of the cell proportion in AMI but not in AI and CI patients (<i>p</i> = 0.001 to 0.05; 0.12 to 0.87 and 0.17 to 0.92 respectively). The amount of myocardial tissue infarcted did not show any correlation with the amount of cellular subpopulations mobilized to peripheral blood (<i>r</i> = 0.10 to 0.20; <i>p</i> = 0.21 to 0.64) from the bone marrow. Conclusion: The proportion of cellular subpopulations with regenerative potential mobilized to circulation during an event of Acute Myocardial Infarction is significantly higher than during an event of acute angina and chronic stable angina, with a significant proportion of mobilized cells that expressed CXCR4, most of which were already in some of the cell cycle phases.
The concept that the heart is unable to regenerate has been invalidated with the emergence of cell therapy, however, and despite multiple clinical trials, it has been difficult to elucidate which subpopulations of bone marrow stem cells, are related to ventricular function improvement, reduction of infarct size, tissue regeneration and angiogenesis [
The cellular necrosis process triggers acute inflammatory events with local accumulation of polymorphonuclear cells and acute phase cytokines such as interleukins and Stem Cell Derived Factor 1 (SDF-1). The latter has shown increases up to 50-fold in the infarct process in experimental models [
The SDF-1:CXCR4 axis acts upon bone marrow to release stem cells to the blood circulation, especially those which express CXCR4, that are then recruited in the myocardial injured. Several experimental studies of myocardial infarction have determined a great variety of stem cells with regenerative and angiogenic activity. These cells usually express CD34, CD133, CD117 and their regenerative capacity is enhanced in the presence of growth factors produced by CD48 stem cells [
Cell therapy has shown beneficial effects on ventricular function and tissue regeneration in patients with acute and chronic myocardial infarction, although with considerable variability in the results, possibly as a consequence of cell proportion, subtype and status of the cells in the cellular cycle, or maybe, by different inflammatory conditions in the heart when cellular implantation is performed [
The study was approved by the hospital research and ethic committees. Patients with myocardial infarction and acute ischemia such as acute angina admitted in the Intensive Coronary Care Unit (ICCU) were recruited and patients with Chronic Ischemia such as chronic stable angina in cardiology and cardiovascular surgery departments were recruited. All of them signed an informed consent. During the first 6 hours of stay of patients with AMI and AI in ICCU, a 10 ml blood sample was obtained from the cephalic vein: 5 ml were collected in an EDTA-containing tube whereas the remaining 5 ml were kept in a non-anticoagulant-containing tube. A similar amount of blood sample was obtained in patients with chronic stable angina (Chronic Ischemia) during hospitalization. All samples were kept at 4˚C.
At arrival to the Intensive Coronary Care Unit, age, gender and cardiovascular risk factors were carefully identified. In all patients upon arrival was taken a 12 derivations electrocardiogram as well as a serum determination of Creatine Kinase-MB and troponine I. All the patients had an echocardiographic study made with a vivid-q echocardiograph with a M4S-RS transducer, for quantification of regional myocardial motility through Bull’s- eye map construction by the following projections: Long axis (APLAX), 2 and 4 cameras.
Peripheral blood mononuclear cells were isolated from the 5 ml through centrifugation for 10 minutes at 250 RPM and the supernatant discarded by adding 500 µl buffer solution. The remaining cells were labeled with spe- cific antibodies and incubated with permeabilizing solution for 10 minutes, then were centrifuged at 250 RPM and kept under refrigeration at 4˚C for 30 minutes.
By cytofluorometry with a FACS caliburcytofluorometer (Becton Dickinson) with a specific FITC-labeled anti human (CD34, CD133, CD117 and CD48) monoclonal antibody (Becton Dickinson) were estimated the percentages as well as the proportions of their cells which expressed CXCR4.
Serum concentration of IL-6 and IL-8 were determined by enzyme immunometric assay sequential solid phase chemiluminesce performed in an automated fashion, with a SIEMENS IMMULITE 1000 Analyzer. The levels of Stem Derived Factor-1 (SDF-1) were indirectly determined by cytofluorometry with a FACS caliburcytofluorometer (Becton Dickinson) using a specific FITC-labeled anti human CD184 monoclonal antibody (Becton Dickinson). The status of the cells subpopulations in the cellular cycle was identified with specific antibodies againts Ki67 (Clon7B11, CEIVD) by flow cytometry (Cytometer Bencton Dikinson 4 channels).
All patients included in the study were divided in 3 groups: 1) Patients with Acute Myocardial Infarction (AMI); 2) Acute Ischemia (AI) such as acute angina and 3) Chronic Ischemia (CI) such as chronic stable angina. For descriptive analysis we used media and DE. The comparisons between groups were made with Student t test for two groups and ANOVA for three groups. For correlation analysis the Spearman Rho test was used. Nominal variables were analyzed with a Chi2 test. We consider statistical significance with a p value of <0.05. The Statistical software SPSS v 20.0 for Windows was used.
We analyzed patients with Acute Myocardial Infarction (n = 67), Acute Ischemia such as acute angina (n = 55) and Chronic Ischemia such as chronic stable angina (n = 52). We did not observe significant differences between groups in age, cardiovascular disease risk factors and amount of myocardial tissue damaged as determined by the echocardiographic study (
The inflammatory cytokines no showed statistical significance between AMI and AI patients, but were significantly higher than CI: IL-6 in AMI 41.4 ± 9.8 pg/ml; AI 40.8 ± 9.7 pg/ml, p = 0.73. AC 9.6 ± 3.1 pg/ml, p = 0.001. IL-8 in AMI 45.6 ± 8.2 pg/ml; AI 43.4 ± 7.4 pg/ml, p = 0.67; CI 8.9 ± 2.7 pg/ml, p = 0.001.
The total amount of cells mobilized into the blood stream was significantly higher in patients with AMI compared with AI and CI patients. The amount of CD34+, CD117+, CD48+ and CD133+ cells showed not significant differences between AMI and AI patients. Interestingly, and despite the apparent lack of differences, the amount of CXCR4+ cells in the AMI patients were significantly higher than those of the AI and CI patients (p < 0.02 to 0.05 and 0.001 respectively). Nearly 40% (29.9% ± 2.1% to 39.1% ± 7.5%) of the CXCR4+ cells in the AMI patients were Ki67+ (
The bivariate analysis showed a significant correlation of the proportional amount of cells positive for the
AMI (n = 67) | AI (n = 55) | CI (n = 52) | p | |
---|---|---|---|---|
Age (years) | 65 ± 11 | 62 ± 10 | 64 ± 9 | 0.84* |
Diabetes Mellitus Evolution in years | 24 7 ± 4 | 20 8 ± 2 | 24 8 ± 3 | 0.18** 0.93* |
Hypertension Evolutión in years | 18 5 ± 2 | 15 6 ± 2 | 26 5 ± 3 | 0.47** 0.68* |
Dyslipidemia Evolutión in years | 13 3 ± 1 | 9 4 ± 1 | 18 3 ± 1 | 0.15** 0.77* |
Segments affected (n) Tissue Infarcted | 4.2 ± 0.7 23 ± 4 | NV NV | 3.9 ± 0.4 25 ± 3 | 0.34 & 0.27* |
Patients with diabetes mellitus, hypertension and dislipidemia are expressed in percentages of total patients in each group, as well as the tissue infarcted; AMI: Acute Myocardial Infarction; AI: Acute Ischemia; CI: Chronic Ischemia; NV: No Value. *ANOVA; **X2; &: Student t test.
AMI | AI | p* | CI | p (&) | |
---|---|---|---|---|---|
Cells × 103/ml SDF-1 | 14.6 ± 1.5 48.9 ± 5.7 | 9.2 ± 1.3 32.5 ± 5.2 | 0.001 0.03 | 6.6 ± 1.1 3.7 ± 1.3 | 0.001 0.001 |
CD48+ CXCR4 KI67 | 35.4 ± 6.7 43.2 ± 4.9 29.9 ± 2.1 | 32 ± 5 28.4 ± 2.1 20.1 ± 4.2 | 0.39 0.05 0.05 | 2.2 ± 0.09 0.30 ± 0.01 5.2 ± 0.8 | 0.001 0.001 0.001 |
CD34+ (%) CXCR4 KI67 | 49.9 ± 3.9 55.7 ± 6.3 36.3 ± 3.6 | 36.7 ± 2.5 27.9 ± 3.4 16.3 ± 1.2 | 0.35 0.03 0.02 | 4.5 ± 1.5 2.8 ± 0.6 1.8 ± 0.02 | 0.001 0.001 0.001 |
CD117+ CXCR4 KI67 | 45 ± 4.7 49.7 ± 6.3 39.1 ± 7.5 | 36 ± 3.2 23 ± 1.6 24 ± 1.1 | 0.37 0.03 0.03 | 4.4 ± 1.5 1.1 ± 1.9 0.7 ± 0.3 | 0.001 0.001 0.001 |
CD133+ CXCR4 KI67 | 43.2 ± 3.7 46.8 ± 7.1 36.1 ± 6.3 | 33.7 ± 5.1 25.6 ± 2.8 10 ± 1.2 | 0.38 0.03 0.001 | 3.9 ± 1.5 2.07 ± 0.67 2.2 ± 0.56 | 0.001 0.001 0.001 |
All the results are expressed as percentage of positive cells in comparison with the total cell count. AMI: Acute Myocardial Infarction; AI: Acute Ischemia; CI: Chronic Ischemia; &: AMI vs AI vs IC comparison; *AMI vs AI comparison; Cellular proportion which express SDF-1 linked to CD184 (CXCR4); Comparisonwith X2 test.
CD’s that we evaluated with SDF-1 expressing in AMI patients (p < 0.01 a 0.04) but not in AI or CI patients (p = 0.12 to 0.87 and 0.17 to 0.92 respectively) (
Cardiac repair and restraint of fibrosis are the consequence of the delivery of progenitor cells into ischemic cardiac muscle, which promotes angiogenesis and revascularization [
AMI | AI | CI | ||||
---|---|---|---|---|---|---|
r | p | r | p | r | p | |
CD117 CXCR4 KI67 | 0.65 0.67 0.59 | 0.02 0.01 0.001 | 0.38 0.61 0.32 | 0.19 0.17 0.26 | 0.21 0.10 0.01 | 0.17 0.49 0.91 |
CD133 CXCR4 KI67 | 0.81 0.66 0.90 | 0.03 0.03 0.02 | 0.39 0.27 0.25 | 0.22 0.40 0.87 | 0.01 0.08 0.03 | 0.92 0.57 0.81 |
CD34 CXCR4 KI67 | 0.61 0.90 0.65 | 0.03 0.02 0.01 | 0.13 0.10 0.11 | 0.59 0.12 0.55 | 0.02 0.12 0.03 | 0.86 0.42 0.42 |
CD48 CXCR4 KI67 | 0.45 0.67 0.51 | 0.12 0.01 0.03 | 0.19 0.32 0.26 | 0.35 0.27 0.36 | 0.16 0.07 0.10 | 0.31 0.65 0.50 |
CD90 CXCR4 KI67 | 0.43 0.49 0.45 | 0.05 0.05 0.04 | 0.33 0.19 0.12 | 0.22 0.43 0.28 | 0.14 0.10 0.11 | 0.37 0.48 0.46 |
AMI: Acute Myocardial Infarction; AI: Acute Ischemia; CI: Chronic Ischemia. Correlation with Spearman Rho.
thology, especially the amount of SDF-1 positive cells circulating and mobilized cells during the early hours of an Acute Myocardial Infarction event, which are completely different to those of an acute angina event and chronic stable angina.
Stromal cell derived factor (SDF-1)-1, acts as a releasing factor for stem cells CXCR4+ in the bone marrow and recruit these stem cells CXCR4+ in the injured tissue [
The differences observed in cellular subpopulations derived from the bone marrow that express CXCR4, may also be explained for the probable over activation of the SDF-1:CXCR4 axis. There are evidence that support the hypothesis that the temporal alignment of this axis is modified by acute hypoxia and cell death [
Inflammatory cytokines increase the presence of bone marrow cell subpopulations [
So far no clinical trials evaluating the efficacy of stem cells derived from the bone marrow in cardiac repair concerning to cell status on cell cycle. This apparently irrelevant information could explain the variations in the results of cardiac regeneration reported in different publications. Our findings show that in patients with Acute Myocardial Infarction, the proportion of cells that express Ki67 which were released into the circulation is significantly higher than in patients with acute angina that did not reach cellular necrosis. This suggests that many cells are released from bone marrow in process of active cell division. This observation reinforces the need to consider this information if we want to improve the cellular therapy efficacy in patients with acute and Chronic Ischemia.
The phenotypic characterization of cellular subpopulations derived from the bone marrow shows that there are three aspects to consider in order to improve cellular therapy for myocardial repair after an infarct event: 1) We must consider the proportion of cells expressing the cell markers involved in tissue repair and angiogenesis (CD34, CD117, CD48, CD133), 2) The proportion of cells that express the CXCR4 marker, and 3) Their cell cycle status.
In summary, our results confirm that the SDF-1 CXCR4 axis reported by Tang et al. [
The proportion of cellular subpopulations with regenerative potential mobilized to circulation during an event of Acute Myocardial Infarction is significantly higher than during an event of acute angina and chronic stable angina with a significant proportion of cells expressing CXCR4, most of which were already in some of the cell cycle phases.